rosuvastatin + fenofibrate

Rosuvastatin + fenofibrate is a fixed-dose combination of two lipid-lowering agents used to treat hyperlipidemia and mixed dyslipidemia. It is indicated for lowering elevated total cholesterol and triglyceride levels to reduce the risk of cardiovascular events such as heart attack and stroke[1][3][6]. - **Rosuvastatin** is an HMG-CoA reductase inhibitor (statin) that works by competitively inhibiting the enzyme responsible for converting HMG-CoA to mevalonate in cholesterol biosynthesis. This leads to decreased hepatic cholesterol concentrations and upregulation of LDL receptors in the liver, increasing clearance of LDL from plasma[5]. - **Fenofibrate** is a fibric acid derivative that activates peroxisome proliferator-activated receptor alpha (PPARα), which increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase. This results in reduced triglycerides and modestly increased HDL cholesterol[6]. The combination provides better control over high cholesterol and triglyceride levels than either agent alone. Common side effects include gastrointestinal disturbances (nausea, diarrhea), muscle pain or weakness (myopathy), abnormal liver function tests, joint pain, headache, elevated creatine kinase levels[3][4]. There are safety concerns regarding increased risk of myopathy/rhabdomyolysis when statins are combined with fibrates; however clinical studies suggest this specific combination is generally well tolerated at standard doses but requires monitoring for adverse effects[2][4].

Brand names

Rozavel FRoseday-FRosuvas FRozucor FNovastat-TGRozat-FCrevast-FRosulip-FRosumac FRozustat F

Other names

fenofibrate + rosuvastatin